BridgeMD
New treatment option for Elderly
Official title Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection
ClinicalTrials.gov ID: NCT07030673
What this study is testing
What is antibiotic withdrawal?
antibiotic withdrawal is an investigational medicine, being studied as a potential treatment for elderly.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Among winter respiratory viruses, influenza is the most common and therefore responsible for the highest mortality, but parainfluenza and RSV viruses have an even higher risk of mortality (1.6 to 1.9 times), this toll being paid mainly by the elderly and co-morbid population. Futhermore, SARS-Cov2 will probably become endemic and/or epidemic with the same targets of fragile patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Patients ≥ 65 years affiliated to a social security scheme
- Hospitalized for a lower respiratory infection defined as:
- the presence of 2 of the following 4 signs:
- hyperthermia \>38°C,
- hyperleukocytosis ≥12000 or ≤4000,
You likely can't join if
- Hospitalization planned for \< 48 hours or transfer planned to another center within 7 days
- Patient in septic shock,
- Febrile aplasia
- Absence of diagnostic microbiological sampling (\> 48 hours after admission)
- Moribund patient,
- Death expected within the week
See the full eligibility criteria
- Patients ≥ 65 years affiliated to a social security scheme
- Hospitalized for a lower respiratory infection defined as:
- the presence of 2 of the following 4 signs:
- hyperthermia \>38°C,
- hyperleukocytosis ≥12000 or ≤4000,
- purulent aspirations/sputum,
- rales on pulmonary auscultation indicating parenchymal damage
- associated with a pulmonary image (standard X-ray, CT scan or ultrasound)
- Microbiological diagnostic sample taken within 48 hours
- Informed consent of the patient or their representative
- Hospitalization planned for \< 48 hours or transfer planned to another center within 7 days
- Patient in septic shock,
- Febrile aplasia
- Absence of diagnostic microbiological sampling (\> 48 hours after admission)
- Moribund patient,
- Death expected within the week
- Inhalation proven by endoscopy or eyewitness
- Purulent pleurisy, lung abscess, or other concomitant bacterial infection requiring antibiotic therapy.
The study team makes the final eligibility decision.
Where it's taking place
- Amiens, France
Compensation & support
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amiens, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.